Belzutifan, an HIF-2α inhibitor, has shown promising results in treating advanced forms of pheochromocytoma or paraganglioma, PNETs, and VHL disease–associated tumors in clinical trials (1). Here, EPAS1 is linked to pheochromocytoma.